A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of BOTOX (Botulinum Toxin Type A) Purified Neurotoxin Complex for the Treatment of Platysma Prominence
Latest Information Update: 06 Jan 2025
At a glance
- Drugs Botulinum-Toxin-A (Primary)
- Indications Muscular disorders
- Focus Adverse reactions; Therapeutic Use
- Sponsors Allergan
- 01 Jan 2025 Primary endpoint (Percentage of Participants With at Least 1-Grade Improvement at Day 14 as Rated by Investigator Using the Clinician Allergan Platysma Prominence Scale (C-APPS))has been met, according to Results published in the Plastic and Reconstructive Surgery.
- 01 Jan 2025 Results assessing onabotulinumtoxinA treatment in adults with moderate to severe platysma prominence , published in the Plastic and Reconstructive Surgery.
- 11 Apr 2023 The protocol has been amended as above-Different time frames has been amended for Pulse Rate, Systolic and Diastolic BP and Respiratory Rate.